206 related articles for article (PubMed ID: 29126266)
1. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
Niessner A; Tamargo J; Koller L; Saely CH; Schmidt TA; Savarese G; Wassmann S; Rosano G; Ceconi C; Torp-Pedersen C; Kaski JC; Kjeldsen KP; Agewall S; Walther T; Drexel H; Lewis BS
Eur Heart J; 2018 Jun; 39(24):2274-2281. PubMed ID: 29126266
[No Abstract] [Full Text] [Related]
2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
Shehadeh N; Raz I; Nakhleh A
Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
[No Abstract] [Full Text] [Related]
5. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
6. The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.
Wu L; Gunton JE
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766545
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
8. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
9. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of diabetes: therapies for type 2 diabetes.
Tsoutsouki J; Wunna W; Chowdhury A; Chowdhury TA
Postgrad Med J; 2020 Oct; 96(1140):610-618. PubMed ID: 32467106
[TBL] [Abstract][Full Text] [Related]
11. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
Choby B
FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
[TBL] [Abstract][Full Text] [Related]
12. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
13. DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.
Sonoda K; Saguil A
Am Fam Physician; 2022 Jul; 106(1):24-25. PubMed ID: 35839371
[No Abstract] [Full Text] [Related]
14. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
Wilding JP; Bain SC
Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
[TBL] [Abstract][Full Text] [Related]
15. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
[TBL] [Abstract][Full Text] [Related]
16. [Novel antidiabetic drugs and cardiovascular complications].
Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
[TBL] [Abstract][Full Text] [Related]
17. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
[TBL] [Abstract][Full Text] [Related]
18. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
19. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
[TBL] [Abstract][Full Text] [Related]
20. Managing postprandial glucose levels in patients with diabetes.
Tenzer-Iglesias P; Brunton S
J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
